Showing 2241-2250 of 4849 results for "".
New in My Practice: Device: Cutera’s AviClear
https://practicaldermatology.com/topics/acne-rosacea/new-in-my-practice-device-cuteras-aviclear/23738/Diverse by Design: The Unique Molecular Footprints of IL-23 Biologics in Psoriasis
https://practicaldermatology.com/issues/april-2024/il23_biologics_in_psoriasis/24457/Christopher Bunick, MD, PhD, discusses a study that explores the structural basis of IL-23 targeted biologic therapies for psoriasis. By mapping the binding sites of these therapies on the IL-23 molecule and correlating molecular properties with clinical efficacy, the study offers insights into whyCosmetic Boot Camp 2018 Presenter Insight
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/cosmetic-boot-camp-2018-presenter-insight/18290/Get up to date on Cosmetic Bootcamp. Presenters provide updates on microneedling, radiofrequency devices, lasers, fillers, neurotoxins, and more. The Cosmetic Bootcamp® provides training and educational opportunities for aesthetic medicine physicians and their staff. Hear from: Mary Lupo, MD; Vic NaThe Inside Scoop on Cosmeceuticals: From Top to Bottom
https://practicaldermatology.com/topics/general-topics/the-inside-scoop-on-cosmeceuticals-from-top-to-bottom/20896/Top derms dish about their favorite cosmeceuticals, including options beyond wrinkle fighting.DERM2024 Meeting Wrap-Up
https://practicaldermatology.com/conferences/derm2024/derm2024-meeting-wrap/26974/DERM2024 Meeting Wrap-UpNoah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsRecent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/22066/DermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/videos/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibilityRepairing the Ellipse; Resident Salary Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/repairing-the-ellipse-resident-salary-update/20414/